CJC-1295
Tested in peopleIt has been tested in people, but it is not an approved medicine. The studies are usually small.
Also called DAC:GRF / Modified GRF 1-29 / Tesamorelin analogue
A long-acting copy of the natural signal for growth hormone release, tested in small early studies in people. Not approved.
The basics
- What is it?
- A long-lasting lab-made copy of the brain signal that tells the body to release growth hormone.
- What do we know?
- Small early studies in people show it raises growth hormone for days after one dose.
- What do we still not know?
- Whether that leads to any real benefit, and what happens with repeated use over time.
Can a doctor prescribe this?
No. Pharmacies are not on record as being allowed to make this into a medicine.
The FDA has not approved this as a medicine.
Not FDA approved and not on the 503A bulks list.
Official status: Not on the 503A bulks list. Checked 2026-06-12.
Lab suppliers we list: 16
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
In animal studies
These are doses given to animals, usually per kilogram of body weight. They do not convert directly to a human dose.
10 mg
horses · under the skin
Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry.Analytical and bioanalytical chemistry · 2013
“The applicability of this multi-analyte method was demonstrated by the detection of N-acetylated LKKTETQ and its metabolite N-acetylated LK from plasma samples obtained after subcutaneous administration of TB-500 (10 mg N-acetylated LKKTETQ) to two thoroughbred geldings.”
2 ng
pigs ·
Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.Drug testing and analysis · 2015
“The method was validated considering the parameters specificity, recovery (11-69%), linearity, imprecision (<25%), limit of detection (5-100 pg in urine, 0.1-2 ng in plasma), and ion suppression.”
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Study in people
The Journal of clinical endocrinology and metabolism · 2006
- A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.
Horse study
Drug testing and analysis · 2019
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.
Horse study
Drug testing and analysis · 2019
- Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth.
Animal study, rats or mice
Proceedings of the National Academy of Sciences of the United States of America · 2009
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Animal study, rats or mice
The Journal of clinical endocrinology and metabolism · 2006
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.
Animal study, rats or mice
American journal of physiology. Endocrinology and metabolism · 2006
- Advances in the detection of growth hormone releasing hormone synthetic analogs.
Lab dish study
Drug testing and analysis · 2021
- Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.
Lab dish study
Analytical and bioanalytical chemistry · 2016
- Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry.
Lab dish study
Analytical and bioanalytical chemistry · 2013
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.
Lab dish study
Endocrinology · 2005
- Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance
Journal not recorded · 2026
- A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.
The Journal of sports medicine and physical fitness · 2026
- Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
Journal of pharmaceutical and biomedical analysis · 2026
- Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.
Journal of mass spectrometry : JMS · 2024
- Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.
Analytical biochemistry · 2023
- Probing for peptidic drugs (2-10 kDa) in doping control blood samples.
Analytical science advances · 2022
- An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.
Journal of pharmaceutical and biomedical analysis · 2022
- Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.
Talanta · 2022
- Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.
Journal of chromatography. A · 2020
- Glycine-modified growth hormone secretagogues identified in seized doping material.
Drug testing and analysis · 2019
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
Substance use & misuse · 2016
- The study of doping market: How to produce intelligence from Internet forums.
Forensic science international · 2016
- Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.
Drug testing and analysis · 2015
- Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.
Expert review of proteomics · 2014
- Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.
Methods (San Diego, Calif.) · 2012
- Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.
Drug testing and analysis · 2010
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2009
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Review of earlier work
Frontiers in endocrinology · 2026
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
Review of earlier work
Frontiers in aging · 2026
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Review of earlier work
Journal not recorded · 2026
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
Review of earlier work
The American journal of sports medicine · 2026
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Review of earlier work
Sports medicine (Auckland, N.Z.) · 2026
- Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
Review of earlier work
JBJS reviews · 2026
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Review of earlier work
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Review of earlier work
Journal not recorded · 2025